Janux Therapeutics Quarterly Cash Flow Statement
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Janux Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Janux Therapeutics generated $12.5 million of operating cash flow and spent $202,000 on capital expenditures. That left free cash flow of $12.3 million, a free-cash-flow margin of 119.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Janux Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -21.97M | -24.36M | -31.95M | -24.31M | -33.86M | -23.51M | -20.22M | -28.06M | -5.96M | -14.76M | -11.76M | -11.57M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 463.00K | 469.00K | 468.00K | 501.00K | 541.00K | 519.00K | 512.00K | 510.00K | 506.00K | 532.00K | 531.00K | 500.00K |
| Stock-Based Compensation | 9.06M | 9.27M | 9.52M | 9.04M | 10.96M | 10.70M | 6.25M | 15.39M | 5.76M | 5.63M | 4.48M | 4.55M |
| Change in Working Capital | 26.82M | 6.28M | -3.07M | 6.46M | 3.66M | -603.00K | -278.00K | 5.51M | -7.25M | -4.45M | -920.00K | -3.23M |
| Operating Cash Flow | 12.48M | -12.34M | -28.54M | -12.86M | -23.81M | -17.02M | -16.73M | -2.23M | -10.02M | -14.84M | -9.90M | -11.71M |
| Capital Expenditures | -202.00K | -273.00K | -106.00K | -93.00K | -473.00K | -371.00K | -42.00K | -25.00K | -95.00K | -197.00K | -515.00K | -470.00K |
| Investing Cash Flow | -38.78M | 8.29M | 29.54M | 8.31M | 1.56M | -340.39M | 33.93M | 12.67M | -190.88M | -113.74M | 11.12M | -61.45M |
| Financing Cash Flow | 2.24M | 3.54M | 2.94M | 493.00K | 954.00K | 554.00K | 386.65M | 1.65M | 2.77M | 322.17M | 831.00K | 56.61M |
| Net Change in Cash | -24.06M | -506.00K | 3.94M | -4.06M | -21.30M | -356.86M | 403.85M | 12.09M | -198.14M | 193.60M | 2.05M | -16.55M |
| Free Cash Flow | 12.28M | -12.61M | -28.65M | -12.95M | -24.29M | -17.39M | -16.77M | -2.26M | -10.12M | -15.03M | -10.42M | -12.18M |
This table shows 12 quarterly periods of Janux Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow JANX's reporting calendar. What is a cash flow statement?